PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 77 filers reported holding PHATHOM PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.36 and the average weighting 1.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $555,397 | -30.8% | 53,558 | -4.5% | 0.00% | – |
Q2 2023 | $803,094 | -55.6% | 56,082 | -77.9% | 0.00% | – |
Q1 2023 | $1,809,883 | +146.4% | 253,485 | +287.2% | 0.00% | – |
Q4 2022 | $734,483 | -6.3% | 65,462 | -7.5% | 0.00% | – |
Q3 2022 | $784,000 | +1.6% | 70,748 | -22.7% | 0.00% | – |
Q2 2022 | $772,000 | -15.0% | 91,544 | +37.3% | 0.00% | – |
Q1 2022 | $908,000 | -37.9% | 66,660 | -10.4% | 0.00% | – |
Q4 2021 | $1,462,000 | -29.4% | 74,391 | +15.3% | 0.00% | – |
Q3 2021 | $2,071,000 | -3.8% | 64,534 | +1.6% | 0.00% | – |
Q2 2021 | $2,152,000 | -11.9% | 63,544 | -2.2% | 0.00% | – |
Q1 2021 | $2,442,000 | +83.9% | 65,004 | +62.6% | 0.00% | – |
Q4 2020 | $1,328,000 | +621.7% | 39,979 | +694.2% | 0.00% | – |
Q3 2020 | $184,000 | +22.7% | 5,034 | +10.5% | 0.00% | – |
Q2 2020 | $150,000 | -63.1% | 4,555 | -71.1% | 0.00% | – |
Q1 2020 | $406,000 | +600.0% | 15,743 | +748.7% | 0.00% | – |
Q4 2019 | $58,000 | – | 1,855 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Medicxi Ventures Management (Jersey) Ltd | 3,760,869 | $39,000,212 | 12.45% |
Frazier Life Sciences Management, L.P. | 10,109,279 | $104,833,223 | 6.96% |
Decheng Capital Management III (Cayman), LLC | 850,000 | $8,814,500 | 2.94% |
Carlyle Group Inc. | 3,496,808 | $36,191,963 | 1.57% |
Ghost Tree Capital, LLC | 395,000 | $4,096,150 | 1.35% |
Newtyn Management, LLC | 500,000 | $5,185,000 | 1.28% |
Altium Capital Management LP | 220,000 | $2,281,400 | 1.19% |
StepStone Group LP | 422,085 | $4,377,021 | 0.98% |
MPM BioImpact LLC | 347,332 | $3,601,833 | 0.96% |
NEA Management Company, LLC | 1,276,595 | $12,238,290 | 0.94% |